For some patients with brain tumors involving regions of the brain related to speech or movement, surgery is performed while the patient is awake, which can improve the procedure’s safety and effectiveness.

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Dr. Dalbagni – who cares for patients with bladder cancer, kidney cancer, penile cancer, and sarcomas – explains treatments offered at Memorial Sloan-Kettering, which can help patients maintain their quality of life.

A study led by Memorial Sloan-Kettering investigators indicates nearly half of all prostate cancer deaths by age 75 occur in a small group of men with high PSA levels at age 45.

Memorial Sloan-Kettering’s Physician-in-Chief, José Baselga, explains the findings from three studies on new targeted therapies for breast cancer.

A new guideline has established standards for testing lung cancer tumors for genetic abnormalities, giving more patients a chance to benefit from targeted therapies.

Dr. Sonoda, who performs minimally invasive procedures when possible, discusses how patients at Memorial Sloan-Kettering have the benefit of an entire team of physicians having input into their care.